Novartis AG reported second-quarter 2025 earnings, raising its full-year forecast. Quarterly sales hit $14.05 billion, almost meeting analyst estimates. Net sales grew 12% year over year with core operating income up 20%. The company also announced a $10 billion share buyback program.

Sales growth was driven by several drugs, including Kisqali, Entresto, Kesimpta, Scemblix, Leqvio, and Pluvicto. Novartis beat earnings expectations with adjusted earnings of $2.42 per share. The company reaffirms high single-digit net sales growth and low double-digit core operating income growth for 2025.

Novartis released topline results from a Phase 3 study on Cosentyx for giant cell arteritis. The drug did not show a significant improvement compared to placebo. The company also announced that CFO Harry Kirsch will retire in March 2026 after a 22-year tenure. CEO Vas Narasimhan expressed confidence in the company’s future growth.

Read more at Yahoo Finance: Novartis Raises Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback (CORRECTED)